ADHD Medication Psychosis Risk: Vulnerability, Screening and Clinical Decision-Making
In this video, Dr Sanil Rege, consultant psychiatrist, examines ADHD medication psychosis risk through a 2025 Lancet Psychiatry synthesis, challenging the reflex assumption that stimulants directly cause psychosis. Instead, he explores baseline psychosis vulnerability in ADHD, reverse causality, and confounding by indication when symptoms emerge during treatment.
Drawing on large cohort data and within-individual study designs, Dr Rege outlines a structured, risk-guided prescribing framework. He discusses the role of family history screening, brief psychosis-like experience measures (PQ-16, PRIME), and CARMS assessment in identifying higher-risk states. The discussion supports clinicians in making balanced prescribing decisions without under-treating ADHD or overlooking emerging psychosis.
Develop Clinical Excellence in ADHD Assessment and Management
Strengthen your clinical skills in ADHD assessment, diagnosis and management through our comprehensive curriculum, covering neurobiology, psychopharmacology, comorbidities and practical case-based learning. Join Academy by Psych Scene to access the courses and earn CME/CPD points.
Get Access to the Course
KEY TAKEAWAYS
- ADHD is associated with an elevated baseline risk of later psychotic disorder, particularly when diagnosed in childhood, independent of medication exposure.
- When psychotic symptoms emerge during treatment, clinicians should consider underlying vulnerability and confounding by indication, rather than assuming direct stimulant causation.
- Psychotic symptoms during stimulant treatment are uncommon but clinically relevant, and most cases resolve after discontinuation without requiring antipsychotic therapy.
- Within-individual pharmacoepidemiological studies do not demonstrate a strong population-level causal signal for methylphenidate, while comparative signals for amphetamines remain confounded.
- A stepwise screening pathway — family history, brief psychosis-like experience measures (PQ-16 or PRIME), and CARMS assessment where indicated — supports proactive, risk-guided prescribing rather than reactive discontinuation.
Clinicians seeking a deeper understanding of psychosis vulnerability and its neurobiological underpinnings may find Schizophrenia: Advanced Clinical Approaches & Training for Psychiatrists particularly relevant. The course explores the pathogenesis of psychotic symptoms, striatal dopamine dysregulation, early identification frameworks, and longitudinal management—concepts central to distinguishing baseline vulnerability from medication effects.
For those focused on ADHD pharmacotherapy, Advanced ADHD Psychopharmacology: Medications, Neuroscience & Prescribing Guidelines for Clinicians extends this discussion through a detailed examination of stimulant and non-stimulant mechanisms, dose considerations, and evidence-informed prescribing strategies.
When medication tolerability or risk profiles shift, Switching Stimulants in ADHD: Advanced Strategies & Training for Psychiatrists & Mental Health Practitioners provides structured guidance on class transitions, comparative pharmacology, and clinical decision-making in complex presentations.
Finally, the Psychopharmacology Masterclass: Advanced Training Series for Psychiatrists & Senior Clinicians offers a broader framework for mechanism-based prescribing across psychiatric disorders, supporting nuanced, risk-guided pharmacological practice.
The Academy by Psych Scene YouTube channel hosts psychiatry lectures and discussions on neuroscience and evidence-based clinical practice.
Related Articles & Videos:
- ADHD Treatment Beyond Stimulants: The Science of Non-Stimulant Medications
- ADHD and Comorbidities: An Evidence-Based Overview of Diagnosis, Treatment, and Clinical Integration
- Australian Clinical Practice Guidelines for ADHD: A Summary for Clinicians
- Evidence Based Summary of the ADHD International Consensus Statement
- What Is ADHD? A Clinical Guide to Diagnosing and Managing Attention Deficit Hyperactivity Disorder
Get Serious About Psychiatry Learning
Our courses offer practical knowledge and clinical expertise at exceptional value, plus CME & CPD points.
Go to Academy by Psych Scene